- The European Commission has granted orphan drug designation to TMB-001, a phase 1 candidate from Timber Pharmaceuticals ( NYSE: TMBR ) for X-linked recessive ichthyosis (XLRI), a rare genetic skin disorder.
- The stock is up 46% in Friday afternoon trading.
- TMB-001 is topical isotretinoin, made using the patented IPEG delivery system.
- The condition is characterized by very dry skin that can be dark brown or light grey that is scaling.
- TMB-001 also has orphan drug designation for autosomal recessive congenital ichthyosis (ARCI) .
- Seeking Alpha's Quant Rating considers Timber ( TMBR ) a strong sell.
For further details see:
Microcap Timber Pharmaceuticals up 46% on orphan drug designation for skin disorder drug